hansoh merck news - Search News

Merck signs up to $2 billion deal for oral weight-loss drug

Reuters on MSN · 2d

Merck signs deal worth up to $2 billion with China's Hansoh for oral obesity drug

Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's experimental oral obesity drug that works similar to the popular weight-loss treatments Wegovy and Zepbound.

YAHOO!Finance · 2d

Merck moves into obesity with deal for Hansoh’s GLP-1 pill

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen as likely buyout targets.

NBC New York · 2d

Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal

Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in payments and royalties on sales.

FiercePharma18h

Fierce Pharma Asia—Merck's oral GLP-1 play; Astellas' gene therapy deal; Betta's FDA nod

Merck in-licensed a preclinical oral GLP-1 candidate from China's Hansoh Pharma. Astellas doubled down in gene therapy with a ...

Pharmalittle: We’re reading about a Merck deal for an obesity pill, a departing FDA official, and more

Merck signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's oral obesity drug ...

FierceBiotech2d

Merck & Co. boosts GLP-1 portfolio by paying $112M upfront for Hansoh's preclinical drug

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a ...

Seeking Alpha on MSN2d

Merck-Hansoh deal for oral GLP-1 hurts obesity drug developers

Viking Therapeutics (NASDAQ:VKTX) and Structure Therapeutics (NASDAQ:GPCR) were among notable decliners on Wednesday after ...

2d

What's Going On With Merck Shares Wednesday?

Merck & Company Inc (NYSE:MRK) shares are trading higher. The company on Wednesday announced a GLP-1 agreement with Chinese ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results